Pacira BioSciences Inc (PCRX)
ROA
Obliczenia
|
2023/Q2 (30 cze 2023) |
2023/Q1 (31 mar 2023) |
2022/Q4 (31 gru 2022) |
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
2021/Q4 (31 gru 2021) |
2021/Q3 (30 wrz 2021) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | -4 568 | -10 455 | 15 909 | 20 881 | 39 234 | 38 439 | 41 980 | 61 624 |
| Aktywa razem | w tys. USD | 1 542 380 | 1 523 420 | 1 681 200 | 1 734 360 | 1 733 990 | 1 891 480 | 2 075 350 | 1 356 000 |
| ROA | -0,30% | -0,69% | 0,95% | 1,20% | 2,26% | 2,03% | 2,02% | 4,54% |
2023/Q2 obliczenia
ROA = Zysk netto (ttm) ÷ Aktywa razem
= $-4 568K ÷ $1 542 380K
= -0,30%
Analiza porównawcza
2023/Q2
Nazwa spółki
Symbol
ROA
Pacira BioSciences Inc
PCRX
-0,30%
Amphastar Pharmaceuticals Inc
AMPH
7,40%
Arcus Biosciences Inc
RCUS
-23,56%
Catalyst Pharmaceuticals Inc
CPRX
26,03%
Corcept Therapeutics Inc
CORT
18,03%
Dynavax Technologies Corp.
DVAX
11,80%
Harmony Biosciences Holdings Inc
HRMY
26,34%
Ironwood Pharmaceuticals Inc
IRWD
-152,07%
Myriad Genetics, Inc.
MYGN
-20,91%
Supernus Pharmaceuticals Inc
SUPN
3,35%
Xencor Inc
XNCR
-16,39%